There are currently 89 active clinical trials seeking participants for Sickle Cell Disease research studies. The states with the highest number of trials for Sickle Cell Disease participants are New York, North Carolina, California and Georgia.
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pociredir
NCT05169580
Recruiting
This is a study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of Pociredir in participants with sickle cell disease.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/28/2025
Locations: University of Arkansas for Medical Sciences (UAMS), Little Rock, Arkansas +19 locations
Conditions: Sickle Cell Disease, Sickle Cell Anemia
Register for Updates
Empowering Adolescents and Young Adults With Sickle Cell Disease as Partners in Treatment Decision Making (EMPOWER-AYA)
NCT05383911
Recruiting
This study will evaluate the acceptability, feasibility, and preliminary efficacy of a shared decision making intervention for adolescents and young adults (AYAs) with sickle cell disease (SCD). 60 AYAs with SCD ages 15-25 and their caregivers and 8 SCD providers will participate in the pilot pragmatic trial. AYAs, caregivers, and providers will be recruited from Nemours Children's Hospital, Delaware (NCH-DE), Nemours Children's Hospital in Orlando, FL (NCH-ORL), and Nemours Children's Health at... Read More
Gender:
ALL
Ages:
15 years and above
Trial Updated:
04/22/2025
Locations: Nemours Children's Hospital, Delaware, Wilmington, Delaware
Conditions: Sickle Cell Disease
Register for Updates
Determination of Red Cell Survival in Sickle Cell Disease and Other Hemoglobinopathies Using Biotin Labeling
NCT06313398
Recruiting
Background: Sickle cell disease (SCD) is an inherited disorder of the blood. SCD causes red blood cells (RBCs) to die early. This can lead to a shortage of healthy cells. SCD and other blood disorders can be managed with drugs or cured with a bone marrow transplant. Researchers want to know how long RBCs survive in people with SCD and other blood disorders before and after treatment compared to those who had a bone marrow transplant. Objective: To learn how long RBCs survive in the body in pe... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
04/22/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Sickle Cell Disease, Thalassemia, Hemoglobinopathy
Register for Updates
Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease
NCT05904093
Recruiting
Background: Sickle cell disease (SCD) is a genetic disease that causes the body to produce abnormal ( sickled ) red blood cells. SCD can cause anemia and life-threatening complications in the lungs, heart, kidney, and nerves. People with SCD are also at increased risk of forming blood clots in the veins and lungs, but the standard treatments for these clots can cause increased bleeding in people with SCD. Better treatments are needed. Objective: To test a drug (fostamatinib) in people with SC... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/18/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Sickle Cell Disease, Hb-SS Disease, Hemoglobin S, Disease Sickle Cell Anemia, Sickle Cell Disorders, Hemoglobin Beta Thalassemia Disease
Register for Updates
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
NCT06439082
Recruiting
A phase III, multi-center, randomized, placebo-controlled, double-blind study to assess efficacy and safety of crizanlizumab (5 mg/kg) versus placebo, with or without hydroxyurea/hydroxycarbamide therapy, in adolescent and adult Sickle Cell Disease patients with frequent vaso-occlusive crises.
Gender:
ALL
Ages:
Between 12 years and 100 years
Trial Updated:
04/18/2025
Locations: Childrens National Hospital, Washington, District of Columbia +8 locations
Conditions: Sickle Cell Disease
Register for Updates
Feasibility and Preliminary Efficacy of Acceptance and Commitment Therapy (ACT) for Sleep Disturbances in Adults With Sickle Cell Disease (SCD)
NCT05457790
Recruiting
Research Type: Clinical Trial Background: People with sickle cell disease (SCD) have many health challenges. Also, they often have trouble sleeping. Acceptance and commitment therapy (ACT) might help people with SCD to improve their sleep problems. Objective: To see how well ACT works in people with SCD and sleep problems and to find out how they feel about it. Eligibility: People between the ages of 18 and 55 with SCD and trouble sleeping. Design: The study is remote. Participants will... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
04/15/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Sickle Cell Disease, Sickle Cell Anemia, Insomnia, Sleeplessness, Transient Insomnia, Nonorganic Insomnia, Chronic Insomnia
Register for Updates
Intravenous L-Citrulline for Vaso-occlusive Pain Episode in Sickle Cell Disease
NCT06635902
Recruiting
The goal of this clinical trial is to learn if intravenous citrulline works to treat acute pain in hospitalized patients with sickle cell disease. It will also learn about the safety of intravenous citrulline. The main questions it aims to answer are: * Does intravenous citrulline decrease the duration of sickle cell pain during hospitalization * What medical problems do participants have when taking intravenous citrulline? Researchers will compare intravenous citrulline to a placebo (a look-al... Read More
Gender:
ALL
Ages:
Between 4 years and 21 years
Trial Updated:
04/14/2025
Locations: Children's National Hospital, Washington, District of Columbia
Conditions: Sickle Cell Disease, Vaso-occlusive Pain Episode
Register for Updates
Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease
NCT04819841
Recruiting
This study is a first-in-human, single-arm, open-label Phase I/II study of nula-cel in approximately 15 participants, diagnosed with severe Sickle Cell Disease. The primary objective is to evaluate safety of the treatment in this patient population, as well as preliminary efficacy and pharmacodynamic data.
Gender:
ALL
Ages:
Between 12 years and 40 years
Trial Updated:
04/10/2025
Locations: Lucile Packard Children's Hospital, Palo Alto, California +2 locations
Conditions: Sickle Cell Disease
Register for Updates
A Research Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
NCT06612268
Recruiting
This study is conducted to confirm whether etavopivat works well at reducing the number of Vaso-occlusive crisis VOCs (sickle cell pain crises) caused by obstructions in blood vessels in adults and adolescents living with sickle cell disease. The study will also evaluate how well etavopivat can reduce the damage to different organs, improve your exercise tolerance and reduce fatigue in people with sickle cell disease.The participants will either get etavopivat or placebo. Which treatment the par... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
04/09/2025
Locations: Uni of Alabama at Birmingham, Birmingham, Alabama +158 locations
Conditions: Sickle Cell Disease
Register for Updates
Ultrasound Acute Chest Syndrome Sickle Cell Disease
NCT06880679
Recruiting
Feasibility and reliability of ultrasound in the inpatient hematology setting.
Gender:
ALL
Ages:
25 years and below
Trial Updated:
04/09/2025
Locations: Indiana University, Indianapolis, Indiana
Conditions: Acute Chest Syndrome, Sickle Cell Disease
Register for Updates
Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study
NCT04657822
Recruiting
This is a multi-center multi-national rollover study to allow continued access to crizanlizumab for patients with sickle cell disease (SCD) who are on crizanlizumab treatment in a Novartis-sponsored study (parent study) and are benefiting from the treatment as judged by the investigator.
Gender:
ALL
Ages:
Between 6 months and 100 years
Trial Updated:
04/09/2025
Locations: University Of Alabama, Birmingham, Alabama +28 locations
Conditions: Sickle Cell Disease
Register for Updates
A Stress and Pain Self-management m-Health App for Adult Outpatients With Sickle Cell Disease
NCT04484272
Recruiting
Our long-term goal is to reduce stress and improve sickle cell disease (SCD) pain control with less opioid use through an intervention with self-management relaxation/distraction exercises (RDE), named You Cope, We Support (YCWS). Americans living with SCD suffer recurrent episodes of acute and chronic pain, both of which are exacerbated by stress. Building on the successes of our prior formative studies, we now propose a well-designed, appropriately powered study to test efficacy of YCWS on out... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
04/02/2025
Locations: University of Florida, Gainesville, Florida
Conditions: Sickle Cell Disease
Register for Updates